Literature DB >> 24071622

Beyond lung cancer: a strategic approach to interpreting screening computed tomography scans on the basis of mortality data from the National Lung Screening Trial.

Caroline Chiles1, Narinder S Paul.   

Abstract

Low-dose computed tomography screening in older patients with a heavy-smoking history can be viewed as an opportunity to screen for smoking-related illnesses and not just for lung cancer. Within the National Lung Screening Trial, 24.1% of all deaths were attributed to lung cancer, but there were significant competing causes of mortality in this patient population. Cardiovascular illness caused 24.8% of deaths. Other neoplasms were listed as the cause of death in 22.3%, and respiratory illness was the cause of death in 10.4%. All of these illnesses might be attributed to smoking. Low-dose computed tomography of the thorax may provide information about these diseases, which could be used to guide therapeutic intervention and, hopefully, alter the courses of these diseases. Information about coronary artery calcification, chronic obstructive pulmonary disease, and potential extrapulmonary malignancy should be provided in the report of the screening examination. This must be balanced against the risk of the burden of false-positive findings and the costs, both psychological and financial, associated with additional investigative evaluations.

Entities:  

Mesh:

Year:  2013        PMID: 24071622     DOI: 10.1097/RTI.0000000000000052

Source DB:  PubMed          Journal:  J Thorac Imaging        ISSN: 0883-5993            Impact factor:   3.000


  3 in total

1.  Lung cancer screening: the path forward.

Authors:  Caroline Chiles; Reginald F Munden
Journal:  Transl Lung Cancer Res       Date:  2018-06

Review 2.  Extrapulmonary neoplasms in lung cancer screening.

Authors:  Myrna C B Godoy; Charles S White; Jeremy J Erasmus; Carol C Wu; Mylene T Truong; Reginald F Munden; Caroline Chiles
Journal:  Transl Lung Cancer Res       Date:  2018-06

3.  Medical Care Costs Were Similar Across the Low-dose Computed Tomography and Chest X-Ray Arms of the National Lung Screening Trial Despite Different Rates of Significant Incidental Findings.

Authors:  Ilana F Gareen; William C Black; Tor D Tosteson; Qianfei Wang; JoRean D Sicks; Anna N A Tosteson
Journal:  Med Care       Date:  2018-05       Impact factor: 2.983

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.